Rafferty Asset Management’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.12M Sell
172,948
-3,911
-2% -$109K 0.02% 452
2025
Q4
$4.9M Buy
176,859
+39,707
+29% +$1.01M 0.02% 439
2025
Q3
$3.33M Buy
137,152
+14,320
+12% +$285K 0.01% 526
2025
Q2
$2.09M Buy
122,832
+2,961
+2% +$51.6K 0.01% 597
2025
Q1
$2.34M Buy
119,871
+8,771
+8% +$230K 0.01% 533
2024
Q4
$2.76M Sell
111,100
-75,991
-41% -$1.94M 0.01% 552
2024
Q3
$4.58M Buy
187,091
+21,827
+13% +$564K 0.02% 441
2024
Q2
$3.87M Sell
165,264
-79,090
-32% -$1.94M 0.01% 474
2024
Q1
$8.07M Sell
244,354
-95,363
-28% -$2.97M 0.03% 343
2023
Q4
$9.25M Sell
339,717
-424
-0.1% -$10.5K 0.04% 302
2023
Q3
$8.18M Buy
340,141
+82,150
+32% +$2.2M 0.05% 279
2023
Q2
$8.24M Buy
257,991
+46,323
+22% +$1.5M 0.05% 261
2023
Q1
$6.48M Buy
211,668
+16,943
+9% +$669K 0.04% 317
2022
Q4
$7.62M Buy
194,725
+70,800
+57% +$3.17M 0.06% 275
2022
Q3
$5.9M Buy
123,925
+2,952
+2% +$168K 0.06% 297
2022
Q2
$4.68M Buy
120,973
+30,590
+34% +$1.22M 0.04% 286
2022
Q1
$5.18M Buy
90,383
+16,604
+23% +$1.09M 0.03% 384
2021
Q4
$5.88M Buy
73,779
+45,173
+158% +$3.87M 0.03% 312
2021
Q3
$2.49M Sell
28,606
-784
-3% -$78.8K 0.02% 565
2021
Q2
$3.78M Sell
29,390
-4,464
-13% -$356K 0.02% 425
2021
Q1
$2.71M Buy
33,854
+23,029
+213% +$2.19M 0.02% 545
2020
Q4
$884K Buy
+10,825
New +$532K 0.01% 535

Other funds holding BEAM

Rafferty Asset Management's BEAM Position: Q1 2026 in Review

Rafferty Asset Management reduced its Beam Therapeutics (BEAM) stake by 2.2% in Q1 2026, selling an estimated $109K and leaving 172,948 shares worth $4.12M. The position accounts for 0.02% of the portfolio, ranked #452.

Rafferty Asset Management first reported a position in BEAM in Q4 2020 and has held it in 22 quarters since. The position peaked at $9.25M in Q4 2023. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Rafferty Asset Management held 172,948 shares of Beam Therapeutics worth $4.12M as of Q1 2026.
  • Rafferty Asset Management sold 3,911 Beam Therapeutics shares in Q1 2026, an estimated $109K.
  • Beam Therapeutics made up 0.02% of Rafferty Asset Management's portfolio in Q1 2026, its #452 holding.
  • Rafferty Asset Management first reported a position in Beam Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Rafferty Asset Management's Beam Therapeutics position peaked at $9.25M in Q4 2023.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.